Investors braced for a bumpy ride ahead of West Pharmaceutical Services'
What analysts say:
- Buy, sell, or hold?: Analysts generally think investors should hang on to West Pharmaceutical Services, with half rating the stock a hold. Analysts like West Pharmaceutical Services better than competitor UniSource Energy overall. Zero out of four analysts rate UniSource Energy a buy compared to one of six for West Pharmaceutical Services. While analysts still rate the stock a moderate sell, they are a little more optimistic about it compared to three months ago.
- Revenue Forecasts: On average, analysts predict $299.4 million in revenue this quarter. That would represent a rise of 6.3% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.67 per share. Estimates range from $0.63 to $0.71.
What our community says:
CAPS All Stars are solidly backing the stock, with 88.5% giving it an "outperform" rating. The community at large backs the All Stars, with 90.6% awarding it a rating of "outperform." Fools are gung-ho about West Pharmaceutical Services, though the message boards have been quiet lately with only 27 posts in the past 30 days. West Pharmaceutical Services' bearish CAPS rating of one out of five stars falls short of the Fool community sentiment.
West Pharmaceutical Services' income has fallen year over year by an average of 14.5%.
One final thing: If you want to keep tabs on West Pharmaceutical Services movements, and for more analysis on the company, make sure you add it to your Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.